Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA(®) trial.
- DOI
- 10.1007/s13340-019-00412-x
- Published
- 2020 Apr
- Container
- Diabetology international
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13340-019-00412-x,
title = {Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA(®) trial.},
author = {Inagaki N and Yang W and Watada H and Ji L and Schnaidt S and Pfarr E and Okamura T and Johansen OE and George JT and von Eynatten M and Rosenstock J and Perkovic V and Wanner C and Cooper ME and Alexander JH and Komuro I and Nangaku M},
year = {2020},
journal = {Diabetology international},
doi = {10.1007/s13340-019-00412-x},
url = {https://doi.org/10.1007/s13340-019-00412-x}
}RIS
TY - JOUR TI - Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA(®) trial. AU - Inagaki N AU - Yang W AU - Watada H AU - Ji L AU - Schnaidt S AU - Pfarr E AU - Okamura T AU - Johansen OE AU - George JT AU - von Eynatten M AU - Rosenstock J AU - Perkovic V AU - Wanner C AU - Cooper ME AU - Alexander JH AU - Komuro I AU - Nangaku M PY - 2020 JO - Diabetology international DO - 10.1007/s13340-019-00412-x UR - https://doi.org/10.1007/s13340-019-00412-x ER -
APA
N, I., W, Y., H, W., L, J., S, S., E, P., T, O., OE, J., JT, G., M, V. E., J, R., V, P., C, W., ME, C., JH, A., I, K., & M, N. (2020). Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA(®) trial.. Diabetology international. https://doi.org/10.1007/s13340-019-00412-x
Source records
- pubmed · retrieved 2026-09-27T07:49:30.769Z